Last updated: July 17, 2026

Application No. 18/423,652

PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Non-Final OA

Filed

Jan 26, 2024

Priority

Jan 30, 2023 — provisional 63/482,133 +1 more

Examiner

MCINTOSH III, TRAVISS C

Art Unit

Tech Center

Assignee

Merck Sharp & Dohme LLC

OA Round

1 (Non-Final)

Interview Optional

— +14.1% interview lift. Interview lift (+14.1%) is below the 15.0% threshold. A written response is recommended.

Based on 1326 resolved cases, 2023–2026

Examiner Intelligence

MCINTOSH III, TRAVISS C View full profile →

Grants 73% — above average

Career Allowance Rate

970 granted / 1326 resolved

+13.2% vs TC avg

Moderate +14% lift

Without

With

+14.1%

Interview Lift

resolved cases with interview

Typical timeline

2y 5m

Avg Prosecution

28 currently pending

Career history

1352

Total Applications

across all art units

Statute-Specific Performance

§101

2.2%

-37.8% vs TC avg

§103

23.9%

-16.1% vs TC avg

§102

27.5%

-12.5% vs TC avg

§112

20.2%

-19.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1326 resolved cases

Prosecution Timeline

Jan 26, 2024

Application Filed

May 07, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/040,309

Patent 12679859

SOPHOROLIPID-CONTAINING COMPOSITION HAVING EXCELLENT HANDLEABILITY

3y 3m to grant Granted Jul 14, 2026

18/196,609

Patent 12678533

PAENIBACILLUS STRAIN, AND HEMOSTATIC POLYSACCHARIDE PRODUCED BY SAME AND USE THEREOF

3y 2m to grant Granted Jul 14, 2026

17/818,856

Patent 12673115

NUCLEIC ACID-PEPTIDE-NUCLEIC ACID CONJUGATE MOLECULES AND METHODS OF MAKING THE SAME

3y 11m to grant Granted Jul 07, 2026

17/993,937

Patent 12673969

CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF

3y 7m to grant Granted Jul 07, 2026

16/479,844

Patent 12667584

ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK

6y 11m to grant Granted Jun 30, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

73%

Grant Probability

87%

With Interview (+14.1%)

2y 5m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1326 resolved cases by this examiner. Grant probability derived from career allowance rate.